News

  • Crossject - AFPric study: patients approve needle-free injection

    Crossject and AFPric, the largest French association of patients with polyarthritis and chronic inflammatory rheumatisms, pursued their collaboration and released today the main findings of a study conducted with members of AFPric on their treatment and their interest in needle-free injection. 

    The study reveals that patients with rheumatoid polyarthritis are largely prepared to use needle-free injection as part of their treatment. 85.9% of respondents are ready to use a needle-free injection device, three quarters of which are currently taking their treatment with injection 

    Read the press release

    Read more
  • CROSSJECT signs a partnership agreement for ZENEO® Methotrexate in China

    CROSSJECT has completed a non-exclusive partnership agreement in China with Xi'an Xiantong Pharmaceutical Research to promote and sale ZENEO® Methotrexate. The agreement with this well-established player in its domestic market allows to estimate a turnover of around € 360 million generated by royalties for ZENEO® Methotrexate over 10 years according to the terms of the contract, to which the profits from the supply contract will be added. "By positioning ZENEO® Methotrexate on a fast growing market potentially representing very big volumes for our drugs, we are in perfect conditions to create value for CROSSJECT and their shareholders," said Patrick Alexandre, President and founder of CROSSJECT. 

    Read more

Events

  • 05/12/2016

    Crossject will be present at the French LIfe Sciences Days 2016

    Crossject will take part in the second edition of the French Life Sciences Days in San Francisco, on June 5th and 6th 2016.
    Contact Tim Muller: tm@scientex.eu or t.muller@crossject.com  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more
  • 04/10/2016

    Kepler Cheuvreux Biotech Days

    Meet us in Paris, June 15th and 16th during the "Kepler Cheuvreux Biotech Days".
    Contact Tim Muller:  tm@scientex.eu or t.muller@crossject.com  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more

video

Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos